{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "XGN", "name": "Exagen Inc.", "url": "https://frontierpicks.com/dossiers/XGN/", "json_url": "https://frontierpicks.com/dossiers/XGN.json", "status": "DORMANT", "current_conviction": "MEDIUM", "graded_conviction": "MEDIUM", "archetype": { "code": "a7", "n": 7 }, "current_thesis": "Post-print re-rating off the 2026-08-04 Q2 beat (revenue $19.941M vs $17.817M consensus, FY26 guide lifted to $72–75M) is now digesting rather than extending: $7.92 on 2026-08-21 to $7.58 on 2026-09-04 with RSI(14) cooling from 86.7 to 65.5, no publicly reported target change since 2026-08-05 and no company-dated event before the ~early-November Q3 print, leaving a maturing narrative that has so far held its gap.", "invalidation_trigger": "A weekly close below $6.36 unwinds the entire 2026-08-04 post-print gap session and returns price to the pre-print range; secondary condition, the ~early-November Q3 2026 print leaving FY2026 guidance unchanged at $72–75M or TTM AVISE CTD ASP printing at or below $446.", "catalyst_date": null, "outcome": "PLAYED_OUT", "outcome_date": "2026-09-18", "invalidation_fired": false, "themes": [ "medtech-diagnostics" ], "tags": [], "sources": [], "notes": [ "Revenue concentration: AVISE CTD was $17.7M of $19.941M total Q2 2026 revenue — one assay franchise carries the model.", "Adjusted EBITDA excludes stock compensation; the Q2 2026 GAAP net loss was $3.2M against $24.6M cash at 2026-06-30.", "ASP is payer-determined: Medicare Clinical Laboratory Fee Schedule and commercial coverage decisions set the $446 TTM per-test price.", "Microcap with a quarterly GAAP loss and no dated disclosure between 2026-09-05 and the ~early-November Q3 print." ], "body_markdown": "## Current Thesis\n\nExagen's thesis is that its August revenue beat and improving test pricing sustain a re-rating toward BTIG's $9 target; a weekly close below $6.36 invalidates that price case. The operating evidence remains the 2026-08-04 results: quarterly revenue of $19.941 million and increased full-year revenue guidance of $72–75 million. [Exagen results](https://investors.exagen.com/news-releases/news-release-details/exagen-inc-reports-second-quarter-2026-financial-results).\n\nThe measured change since the September 5 note is price strength: the adjusted close advanced from $7.58 on 2026-09-04 to $8.41 on 2026-09-18. Coverage also resumed: TipRanks reports a B. Riley coverage transfer on 2026-09-11 with its $12 target unchanged. That corrects the earlier description of stopped coverage, but supplies no higher valuation target. [Reported analyst action](https://www.tipranks.com/stocks/xgn/forecast).\n\nThe narrative is maturing — this is an inference from the unchanged September 11 target and the September 17 publication of the existing August earnings-call transcript. Neither item establishes a new operating acceleration. The lifecycle assessment would change if fresh results improved the August guidance and the market closed above the September 18 reference close. [Transcript publication](https://www.benzinga.com/news/26/09/61837474/full-transcript-exagen-q2-2026-earnings-call).\n\n## Bull Case\n\n- **Pricing and volume improved together.** Exagen's 2026-08-04 release reported an AVISE CTD trailing-twelve-month average selling price (ASP) of $446 per test, up 4% year over year, alongside 11% test-volume growth. [Company results](https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/q22026exagenearningspressr.htm).\n- **Operating losses narrowed materially.** For Q2 2026, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) showed a $0.1 million loss, compared with a $1.7 million loss a year earlier; gross margin reached 61.3%. These are measured improvements, not evidence that cash breakeven has arrived. [Company results](https://investors.exagen.com/news-releases/news-release-details/exagen-inc-reports-second-quarter-2026-financial-results).\n- **Analyst valuation support persisted.** B. Riley's reported 2026-09-11 action retained a $12 target, following the August reset. It supports continuity of that analyst's view rather than a fresh target increase. [Reported analyst action](https://www.tipranks.com/stocks/xgn/forecast).\n\n## Bear Case\n\n- **Adjusted profitability leaves a gap.** Exagen reported a Q2 2026 net loss under generally accepted accounting principles (GAAP) of $3.2 million and approximately $24.6 million of cash at 2026-06-30. Its adjusted EBITDA calculation excludes stock compensation and other items. [Company results and reconciliation](https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/q22026exagenearningspressr.htm).\n- **One assay dominates revenue.** The August 4 results attributed $17.7 million of Q2 2026 revenue to AVISE CTD.\n- **Recent publication adds no quarter.** Benzinga's 2026-09-17 transcript concerns the quarter ended 2026-06-30. Its publication date does not establish a September earnings beat or updated guidance. [Transcript](https://www.benzinga.com/news/26/09/61837474/full-transcript-exagen-q2-2026-earnings-call).\n\n## Setup & Price Structure\n\nThe 2026-09-18 adjusted reference close was $8.41, with a three-month price increase of 90.3%. The 14-day relative strength index (RSI) measured 68.2, versus 65.5 on 2026-09-04. Price remained 29.7% below the adjusted 52-week high of $11.96, according to the supplied September 18 daily-bar snapshot. These observations establish stronger price momentum; they do not identify who supplied demand.\n\nThe price case is fulfilled by a weekly close at or above BTIG's $9 target, reported on 2026-08-05, before a weekly close below $6.36. The latter is the August 4 gap-session reference retained from the prior published analysis, not the pre-earnings close. [BTIG target history](https://www.benzinga.com/quote/XGN/price-targets).\n\nThe positioning evidence is limited. Analyst revisions clustered on 2026-08-05, followed by B. Riley's unchanged September 11 target. The September 2 Form 4 described the CFO's September 1 disposal as issuer-mandated tax withholding on restricted stock unit vesting, which does not establish discretionary selling. No current retail-participation series, short-interest series or moving-average measurement is supplied; crowding cannot be established from the price gain alone.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-30, estimated — myositis training checkpoint.** On the August 4 call, management placed sales-force training at the end of Q3 ahead of the planned early-2027 launch. This is an operational timetable, with no scheduled public disclosure attached; later confirmation of a delay would weaken the product-expansion case. [Call transcript published September 17](https://www.benzinga.com/news/26/09/61837474/full-transcript-exagen-q2-2026-earnings-call).\n- **~2026-11-03, estimated — Q3 results.** This later event is the operating test for the thesis: updated ASP and full-year guidance can confirm or contradict the August improvement. MarketBeat lists November 3 as estimated and explicitly states that Exagen has not confirmed the date. [Earnings calendar](https://www.marketbeat.com/stocks/NASDAQ/XGN/earnings/).\n\nAs checked on 2026-09-20, Exagen's investor-relations page lists no upcoming event. No company-confirmed disclosure catalyst has been established within the next 30 days. [Exagen investor relations](https://exagen.gcs-web.com/).\n\n## What Would Change Our Mind\n\nLoss of the August earnings-session reference would end the price thesis: a weekly close below $6.36 is the observable failure condition. Separately, the next results would contradict the operating case if management reduced its August 4 full-year revenue guidance of $72–75 million or reported trailing-twelve-month AVISE CTD ASP at or below $446 per test. Unchanged revenue guidance alone would not demonstrate deterioration; it would leave the existing range intact.\n\n## Correlation Notes\n\nThis remains a single-name diagnostics setup. The supplied 2026-09-18 snapshot establishes Exagen's three-month price increase but includes no matched sector or benchmark return series. It cannot support a measured correlation claim or establish that a group move explains the advance. The company-specific mechanism is the pricing and volume improvement reported on August 4; attribution of subsequent share-price strength to that mechanism remains an inference.", "first_seen": "2026-08-20", "last_analyzed": "2026-09-19T22:30:15+00:00", "last_synthesized": "2026-09-19", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }